1. Pink Sheet
  2. >>Advanced Technologies
  3. >>Cell & Gene Therapies

CMS Layoffs Broader Than Reports Indicate, Former Administrator Brooks-LaSure Says

 
• By Cathy Kelly

The "interwoven" nature of the offices within the agency likely means Medicare and Medicaid benefits may be disrupted by staff cuts despite assurances from the administration, Brooks-LaSure warned.

CMS employees were laid off without official explanation or tally from the Trump Administration. (Shutterstock)
Key Takeaways
  • CMS staff cuts go beyond those at the payment model innovation center and the center overseeing commercial plans, a former agency administrator Chiquita Brooks-LaSure said.
  • The layoffs likely will impact Medicare and Medicaid benefits, despite administration assurances otherwise, she suggested.
  • Layoffs at the Center for Medicare and Medicaid Innovation raise questions about the future of the Cell and Gene Therapy Access Model now underway, but also add uncertainty about the Trump Administration's approach to CMMI models aimed at lowering drug prices.

The extent of the Trump Administration’s layoffs at the US Centers for Medicare and Medicaid Services is unclear, but do go beyond reported cuts at the CMS innovation center and...

“There are reports of cuts to a couple of the offices” within CMS “but it is my understanding that those cuts are more broad,” she said during a 19 February...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell & Gene Therapies

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

Keep Talking: US FDA’s Beleaguered Biologics Center Remains Vital To Regenerative Medicine

 
• By Bridget Silverman

Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.

Tougher Approval Standards May Follow Vinay Prasad’s Appointment To Lead US FDA’s CBER

 
• By Sarah Karlin-Smith

Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.

More from Geography

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.